Our findings also reveal, for the first time, that TIMP-1, classified among OXSRDEGs, is upregulated in both UC and CRC, with enrichment in tumor signaling pathways, such as TGF-β, probably marking it as a novel anticancer therapeutic target. This evidence concerns the gene TIMP1 and colorectal carcinoma.